Podcasts about Biostatistics

Carly Brantner is an assistant professor of Biostatistics & Bioinformatics at Duke University and Duke Clinical Research Institute. Resources from this episode: multicate: R package for estimating conditional average treatment effects across one or more studies using machine learning methods PCORnet® Front Door: Access point for potential investigators, patient groups, and other stakeholders to connect with PCORnet and get support for potential research studies Patient-Centered Outcomes Data Repository (PDOCR): De-identified data from 24 (and counting) PCORI-funded studies Follow along on Bluesky: Carly: @carlybrantner.bsky.social Ellie: @epiellie.bsky.social Lucy: @lucystats.bsky.social  

Drs. Jeffrey Jensen and Johanna Richey welcome Dr. Najwa Javed to Dean's Chat! Dr. Javed is a board certified podiatrist and founder of E'MAR Italy. She holds a Bachelor of Science in Biochemistry and Ethno-Anthropology from the University of Oklahoma and she has a Masters of Public Health in Biostatistics and Clinical Research with honors from the University of North Texas Health Science Center. This episode is sponsored by Bako Diagnostics! Dr. Javad received her Doctorate of Podiatric Medicine from the College of Podiatric medicine with Samuel Merritt University and she completed her surgical residency training program through the VA Palo Alto conjunction with Stanford university consortium. Join us, as she discusses the inspiration from experiences with her grandmother's health they got her interested in medicine.   Dr. Javed is the managing partner and CEO of Silicon Valley Podiatry Group and she's also the founder of E'MAR Italy, a luxury footwear brand built with patent pending medical technology for the modern women. Tune in, as we discuss “all things podiatric medicine” for this special entrepreneur episode!  She is part of the Female Founder Collective, a network of businesses led by women, supporting women. Her company won FAST Company's World Changing ideas Award, the Paysafe Entreprenista Pitch Competition and has been featured in several media outlets! She was recently featured as a speaker at the Synergy OPEN Silicone Valley Forum talking about “Scaling while staying private.” She is the recipient of the Philip Gardner award for excellence in podiatric medicine and she brings unique expertise as both practicing physician as well as Silicon Valley founder, and entrepreneur.  We hope you enjoy! https://najwajaved.com/ https://shopemar.shop/ https://bmef.org/ https://www.apma.org/

Dr. Naveen PrabakaranAssoc. Prof - Biochemistry | Pseudoscience Antagonist | Scientific Content WriterDr.

Send us a textWhat happens when passion meets purpose in the world of medical data? Dr. Okechinyere Achilonu takes us through her journey in the evolving landscape of biostatistics in Africa.She reveals how this often-overlooked field serves as the backbone of health research across the continent.Born in Nigeria, Dr Okechi is currently a lecturer and biostatistician at the University of Witwatersrand in South Africa. She also shares the impact of the Sub-Saharan Africa Advanced Consortium for Biostatistics (SACAB) on her career. Speaking about data and research, have you heard about Jenni AI, a research assistant that can write, cite and edit? Try it for any academic research related work and notice the difference!Support the showFollow the show on:Twitter: @RootofscipodInstagram: @Rootofscipod YouTube: The Root Of The Science PodcastFacebook: The Root of The Science Podcast LinkedIn: The Root Of The Science PodcastWebsite

Dr. Cynthia Bulik is a clinical psychologist and one of the world's leading experts on eating disorders. She is the Founding Director of the University of North Carolina Center of Excellence for Eating Disorders and also the founder director of the Centre for Eating Disorders Innovation at Karolinska Institutet in Stockholm, Sweden. Dr. Bulik is Distinguished Professor of Eating Disorders in the Department of Psychiatry at UNC, Professor of Nutrition in the Gillings School of Global Public Health, and Professor of Medical Epidemiology and Biostatistics at Karolinska Institute.  Dr Bulik has received numerous awards for her pioneering work, including Lifetime Achievement Awards from the National Eating Disorders Association, the Academy for Eating Disorders, and the International Society of Psychiatric Genetics. She has written over 750 scientific papers, and several books aimed at educating the public about eating disorders.  Currently, Dr. Bulik's focus  is in the reconceptualization of eating disorders as being a metabo-psychiatric diseases. Food Junkies is keen to explore this interest in how metabolic disease plays a role in disordered eating: can this construct be the  common ground to start to understand the muddy waters  between eating disorders and food addiction?  In This Episode, You'll Learn:

After a nearly four-year delay, the Central government finally released a whole lot of reports about India's births, deaths and health indicators for the year 2021. Two of these key reports, released by the Registrar General of India, were the number of deaths registered, and the medical certification of the causes of deaths. What did these reports find? In 2021, the year of the brutal and devastating Delta strain of Covid-19, India recorded 21 lakh more deaths than it did in 2020. As of May 19 this year however, the COVID-19 dashboard maintained by the Union Ministry of Health says that the total number of Covid19 deaths in India so far stands at 5,33,666. So what caused these 21 lakh excess deaths? If the pandemic had not occurred would such a high number of deaths have been recorded? Why is there such a wide difference among States on the number of Covid fatalities vs the number of registered deaths that year? What does medical certification of causes tell us? And do we need a better system to track, register and attribute causes of death in India? Guest: Bhramar Mukherjee Senior Associate Dean of Public Health Data Science and Data Equity; Anna M.R. Lauder Professor of Biostatistics; Professor of Epidemiology (Chronic Diseases) and of Statistics and Data Science Host: Zubeda Hamid Edited by Sharmada Venkatasubramanian Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode Lucy and Ellie dig into a recently publicized paper, "Vaccination and Neurodevelopmental Disorders: A Study of Nine-Year-Old Children Enrolled in Medicaid", which has gained attention after being promoted by RFK Jr. as evidence that vaccines cause autism.    Ellie breaks down her Substack critique of the study. Together, she and Lucy discuss the methodological flaws and what a better version of this study might look like.   Vaccination and Neurodevelopmental Disorders: A Study of Nine-Year-Old Children Enrolled in Medicaid: https://publichealthpolicyjournal.com/vaccination-and-neurodevelopmental-disorders-a-study-of-nine-year-old-children-enrolled-in-medicaid/ RFK Jr is promoting a new study claiming "vaccines cause autism" but it doesn't add up. Literally [Ellie's substack]: https://epiellie.substack.com/p/rfk-jr-is-promoting-a-new-study-claiming   Follow along on Bluesky: Ellie: @epiellie.bsky.social Lucy: @lucystats.bsky.social  

Title: Journal Club Series Episode 12- Regression (eg, linear, logistic, survival analysis) Target Audience This activity is directed to physicians, medical students, nurse practitioners, nurses, and physician assistants. Objectives: Upon completion of this activity, participants should be able to: •      Describe the concept of regression. •      Differentiate between linear and logistic regression. •      Interpret survival analysis.  Course Directors: Tony R. Tarchichi MD — Associate Professor, Department of Pediatrics, Children's Hospital of Pittsburgh of the University of Pittsburgh Medical Center (UPMC.) Paul C. Gaffney Division of Pediatric Hospital Medicine. No relationships with industry relevant to the content of this educational activity have been disclosed. Jenna Carlson Ph.D — Assistant Professor of Human Genetics and Biostatistics, University of Pittsburgh No relationships with industry relevant to the content of this educational activity have been disclosed. Conflict of Interest Disclosure: No other planners, members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose. Accreditation Statement: In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. The University of Pittsburgh School of Medicine designates this enduring material activity for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.   Disclaimer Statement: The information presented at this activity represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the UPMC Center for Continuing Education in the Health Sciences, UPMC / University of Pittsburgh Medical Center or Affiliates and University of Pittsburgh School of Medicine.  Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses. Released 4/15/2025,  Expires 4/15/2028 The direct link to the course is provided below: https://cme.hs.pitt.edu/ISER/app/learner/loadModule?moduleId=25795&dev=true

Vincent Arel-Bundock is a professor at the Université de Montréal, where he studies comparative and international political economy. Vincent's website: https://arelbundock.com/ Vincent's book "Model to Meaning: How to Interpret Statistical Models With marginaleffects for R and Python": https://marginaleffects.com/     Follow along on Bluesky: Vincent: @vincentab.bsky.social Ellie: @epiellie.bsky.social Lucy: @lucystats.bsky.social    

My fabulous guest this week, Dr. Audrey Schnell, and I found ourselves very aligned in the discussion of her work as a trailblazer in personal development and transformation. Specifically the potential for Humanity as a whole to move into a much more abundant, prosperous, and enjoyable era and for individuals to reach their full, magnificent ability. This is a theme throughout her work, Dr. Schnell is renowned for her deep expertise, she has spent decades empowering individuals to break through their barriers and unlock their full potential. Dr. Schnell can uniquely pinpoint the hidden roots of self-sabotage and offer transformative guidance that leads to profound, lasting change. On this guest episode, Dr. Schnell speaks with us from the comfort of her amazing off-grid home in West Virginia. She shares about her experience starting out in the field of Epidemiology and Biostatistics, studying why and how people change for over 40 years. She goes on to share how she got into the coaching business and how health and wealth together are the foundation of success, what self-sabotage really is and how to get out of your own way.Bio:Dr. Schnell has an M.A. in Clinical Psychology and a Ph.D. in Epidemiology and Biostatistics.  She has been studying why and how people change for over 40 years. Audrey Schnell enables her clients to end self sabotage, stop derailing themselves, master their emotions and reach their goals. She helps people see the blind spots that are costing them money and eliminate emotional triggers so they can reach their potential, create long-term client relationships, and even turn difficult clients into success stores. She has been a featured speaker at retreats, been a valued guest on numerous industry podcasts and founded 2 successful online summits that featured over 20 top-flight experts from the world of healing and peak performance. Audrey lives off the grid on 40 Acres in rural West Virginia with her husband and dogs. Email: audrey@audreyschnellphd.comWebsite: www.audreyschnell.comFacebook: Audrey Schnell Instagram : audreyschnellphdLinktree : https://linktr.ee/audreyschnellLinkedin :Audrey Schnellhttps://audreyschnell.kartra.com/calendar/ZoomwithAudrey* Women Waken Wednesdays will be held weekly on Wednesdays at 6pm PST starting in February! This is a virtual Women's group I'm holding for my beautiful listeners. I would love for you to join! Please contact me (IG or Email) for Zoom info!Donations To Women Waken To Support The Show Are Greatly Appreciated

John Quackenbush, chair of the Department of Biostatistics at Harvard's T.H. Chan School of Public Health, joins WBUR's Morning Edition to discuss what the freeze means for his work.

Episode Overview   In this unfiltered and dynamic episode of Higher Density Living, host Jason Rigby sits down with Dr. Audrey Schnell, an emotional intelligence expert with over 40 years of experience studying human behavior, self-sabotage, and personal transformation. With an M.A. in Clinical Psychology and a Ph.D. in Epidemiology and Biostatistics, Dr. Schnell brings a unique blend of science-backed insight and practical wisdom to the conversation. She's spent decades helping clients—from entrepreneurs to everyday individuals—end self-sabotage, master their emotions, and unlock their potential. Together, Jason and Dr. Schnell dive into the messy truths of emotions, boundaries, and productivity, offering actionable strategies to turbocharge emotional intelligence and live a more intentional life.   Guest Bio: Dr. Audrey Schnell Credentials: M.A. in Clinical Psychology, Ph.D. in Epidemiology and Biostatistics Experience: Over 40 years researching why and how people change Mission: Enables clients to stop self-sabotage, eliminate emotional triggers, and achieve their goals by identifying blind spots and mastering emotions Impact: Helps individuals and businesses build long-term relationships, turn difficult clients into success stories, and reach peak performance Achievements: Featured speaker at retreats, frequent podcast guest, and founder of two successful online summits featuring 20+ top experts in healing and peak performance Personal Life: Lives off-grid on 40 acres in rural West Virginia with her husband and dogs Website: audreyschnell.com     Key Topics Discussed   Boundaries: The Ultimate Power Move (00:36 - 06:51) Why We Struggle with Boundaries: Dr. Schnell explains that boundaries are less about others and more about self-care—what we're willing to accept or not. Many fail to set them due to a need to be liked, hypervigilance, or fear of rejection. Practical Tip: For entrepreneurs, set time boundaries (e.g., no client texts at 6 a.m. unless it's a true emergency). A simple automated response like “I've seen your message and will reply soon” can ease the pressure. Jason's Insight: Entrepreneurs often get addicted to busyness, feeding off high cortisol levels and the need to feel wanted. Saying No to Good Things: Dr. Schnell highlights the challenge of rejecting appealing opportunities that derail focus—a lesson reinforced by Jason's anecdote about a billionaire who mastered saying “no” to amazing offers.   2.  Emotional Intelligence for Everyone (12:14 - 18:22) Underrated EI Skill: Empathy is the game-changer we're sleeping on. It's about understanding others' feelings, not just feeling them (empathy vs. sympathy). Cultural Traps: Jason notes society's victimhood obsession, asking how narcissists can develop empathy. Dr. Schnell debunks the overuse of “narcissist” labels and urges people to escape survival mode to unlock self-awareness and empathy. Practical Application: In relationships, aim to connect, not win. Start conversations from shared goals (e.g., “We both want to retire by 70”) and ask curious questions like “What made you say that?” instead of arguing.   3. The Science of Getting Things Done (09:15 - 11:41, 21:24 - 28:10) Dr. Schnell's Journey: Her shift from clinical psychology to research (sparked by the rise of computers in the ‘80s) taught her discipline and the power of starting overwhelming projects. Fear of Finishing: People avoid completing projects due to fear of imperfection or uncertainty about “what's next.” Dr. Schnell calls BS on perfectionism—it's often avoidance or lack of commitment, not a noble trait. Discipline Equals Freedom: Procrastination stems from relying on urgency rather than motivation. Jason ties this to his own shift from fear-driven hustle to intentional discipline, noting it protects the nervous system.   4. Dumbest Emotional Traps and How to Escape (29:09 - 37:18) The Trap: Worry and selfishness top the list. Worry is “praying for the outcome you don't want,” draining energy without purpose. Selfishness shows up when we obsess over ourselves instead of serving others (e.g., coaches fixating on client perceptions). Climbing Out: Take care of your nervous system first—hunger and fatigue amplify toddler-like meltdowns. Self-awareness is key: name your feelings (e.g., “I'm agitated”) to contain them, and don't trust them as facts. Jason's Take: Society's feelings-obsession (especially among younger generations) reflects a pendulum swing from repression to indulgence, fueled by our brain's energy-conserving wiring.   5. Decision-Making and Overthinking (38:58 - 44:26) Why We Overthink: Survival instincts overestimate task difficulty and underestimate post-task relief, stalling action. Visualization can trick the brain into thinking a job's done, reducing motivation. Solutions: Set a timer for 15 minutes to start, lean on discipline over habits, and anchor decisions to identity (e.g., “I'm not an average person” stopped Dr. Schnell from mindless scrolling). Jason's Game: He challenges his ego's comfort-seeking, realizing unchecked indulgence leads to stagnation.   6. Saying No Without Guilt (46:24 - 50:04) The Guilt Trap: People (especially women, per Jason) say “yes” to draining relationships or tasks to avoid discomfort. Guilt isn't inherently bad—it can motivate—but unchecked, it's self-focused. How to Say No: Reflect on the “why” behind guilt (e.g., “Will I feel like a bad person?”). Weigh the cost to yourself vs. others, and practice sitting with uncomfortable feelings instead of caving.   7. Three No-BS EI Strategies (51:50 - 55:00) Watch More TV: Observe others' behaviors in media to spot what you don't want to emulate (e.g., whining). Feel Your Feelings: Name and own them—don't suppress or over-trust them for decisions. Believe in Yourself: Focus on competence and courage, not fleeting confidence. Practice beats imposter syndrome every time.   Memorable Quotes Dr. Schnell: “Boundaries are really about us and what we are willing and not willing to do.” Jason: “We can get so caught up in daily tasks that we look at people as ‘Did you perform?' instead of having empathy for them as a human.” Dr. Schnell: “If one more person says they work better under pressure, nobody works better under pressure—they just work.” Dr. Schnell: “Feelings aren't facts. Don't trust your feelings.” Jason: “Discipline equals freedom—that's so true.” Dr. Schnell: “What you name, you contain.”     Resources Mentioned Dr. Schnell's Website: audreyschnell.com Upcoming Docu-Series: “How to Have Vibrant Health, Wealth, Freedom, and Live the Life You Desire” – Launches April 1, 2025 (details on her website, Facebook, and LinkedIn) Social Media: Follow Dr. Schnell on Facebook and LinkedIn     Final Thoughts   This episode is a masterclass in emotional intelligence, blending Dr. Schnell's 40 years of expertise with Jason's relatable insights as an entrepreneur and seeker of higher living. From setting boundaries to escaping emotional traps, their conversation cuts through the noise with no-BS strategies anyone can apply. Whether you're running a business or just running your life, this deep dive will leave you equipped to master your emotions and reach your goals.   Visit audreyschnell.com to explore Dr. Schnell's coaching, blog, and upcoming docu-series. Subscribe to Higher Density Living for more unfiltered wisdom!

As regulatory expectations evolve under the FDA's Project Optimus oncology dosing initiative, biostatistics is emerging as a central pillar in designing and executing trials that move beyond the traditional maximum tolerated dose (MTD) approach.In this fourth episode of our Project Optimus series, host Dr. Wael Harb is joined by biostatistics expert X.Q Xue, PhD, Vice President and Global Head, Biostatistics at Syneos Health to explore how statistical science is transforming dose optimization in oncology drug development. Dr. Xue discusses the limitations of legacy 3+3 dose-escalation designs and introduces innovative alternatives, including Bayesian modeling, adaptive trial strategies and randomized parallel dose-response studies, which support more precise dose selection and can ultimately improve patient outcomes and trial efficiency.Together, Drs. Harb and Xue examine how smaller biotech companies can overcome barriers to implementation, the role of simulation and AI in trial planning and how a biostatistics-driven approach may increase the likelihood of late-phase success, reduce post-marketing adjustments and support faster regulatory approvals.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Noah Greifer is a statistical consultant and programmer at Harvard University. Episode notes: WeightIt package: https://ngreifer.github.io/WeightIt/ MatchIt package: https://kosukeimai.github.io/MatchIt/ Noah's awesome Stack Exchange post: https://stats.stackexchange.com/a/544958 Follow along on Bluesky: Noah: @noahgreifer.bsky.social Ellie: @EpiEllie.bsky.social Lucy: @LucyStats.bsky.social

Dr. Michael Muehlenbein is a prominent figure in anthropology and biology, currently serving as a professor at Baylor University. His academic journey has been marked by a deep commitment to understanding human evolution, behavior, and health through an interdisciplinary lens. Michael earned an MsPH in both Tropical Medicine and Biostatistics from Tulane University, and an MPhil and PhD in Biological Anthropology from Yale University. His research interests are diverse, encompassing topics such as the evolutionary basis of disease susceptibility, reproductive strategies, and the interplay between environmental factors and human physiology. At Baylor, he has contributed significantly to both teaching and research, mentoring students while also publishing extensively in peer reviewed journals. His work often integrates insights from evolutionary theory with practical applications in public health and medicine, making him a key contributor to discussions on how our evolutionary past shapes contemporary health challenges. Michael is also the Co PI on the NSF-funded project, “Shared markers of identity on inflammation and stress.” ------------------------------ Find the papers discussed in this episode: Muehlenbein MP, Gassen J, Nowak TJ, Henderson AD, Weaver SP, Baker EJ. (2023). Waco COVID Survey: A Community-Based SARS-CoV-2 Serological Surveillance Study in Central Texas. J Community Health, 48(1):104-112. doi: 10.1007/s10900-022-01143-y. Muehlenbein M, Gassen J, Nowak T, Henderson A, Morris B, Weaver S, Baker E. (2023). Age-Dependent Relationships Between Disease Risk and Testosterone Levels: Relevance to COVID-19 Disease. Am J Mens Health. doi: 10.1177/15579883221130195. ------------------------------ Contact Dr. Michael Muehlenbein: Michael_Muehlenbein@baylor.edu ------------------------------ Contact the Sausage of Science Podcast and Human Biology Association: Facebook: facebook.com/groups/humanbiologyassociation/, Website: humbio.org, Twitter: @HumBioAssoc Chris Lynn, Co-Host, Website: cdlynn.people.ua.edu, E-mail: cdlynn@ua.edu, Twitter: @Chris_Ly Courtney Manthey, Guest-Co-Host, HBA Junior Fellow , Website: holylaetoli.com/ E-mail: cpierce4@uccs.edu, Twitter: @HolyLaetoli Anahi Ruderman, SoS Co-Producer, HBA Junior Fellow, E-mail: aniruderman@gmail.com, Twitter: @ani_ruderman

For this episode, we discuss the roles and sensitivity of mitochondria with Dr. Richard Frye, MD, PhD. Dr. Frye received an MD and a PhD in Physiology and Biophysics from Georgetown University. He is board certified in Pediatrics, Neurology with special competence in Child Neurology, and as a Certified Principal Investigator. In addition, he has a Masters in Biomedical Sciences and Biostatistics from Drexel University. Dr. Frye has over 300 publications in leading journals and book chapters.Dr. Frye shares many figures during the conversation so the listener can follow along.Dr. Richard Frye https://drfryemdphd.comRossingnol Medical Center Facebook https://www.facebook.com/RossignolMedicalCenterNeurological Health Foundation https://neurologicalhealth.orgHealthy Child Guide https://neurologicalhealth.org/the-guide-5/Daylight Computer Company https://daylightcomputer.com?sca_ref=8231379.3e0N25Wg3wuse "autism" in the discount code for $25 coupon.This is the future of tech.Chroma Light Therapy https://getchroma.co/?ref=autismuse "autism" for a 10% discount,0:00 Dr. Richard Frye0:58 Daylight Computer Company5:17 Chroma Light Devices8:27 History of Leucovorin; low risk, high reward; Folate Receptor Alpha (FRa)10:25 Blood Brain Barrier; Folate; CSF (cerebral spinal fluid)14:04 DNA, RNA; MTHFR (Methylenetetrahydrofolate reductase)17:34 Cerebral Folate deficiency; BH4, Placenta & Womb23:35 Folate deficiency & Autism26:21 Clinical Studies & Data29:28 Folate & Mitochondria; Cerebral Folate Antibodies; White Matter Findings (!)34:45 Cerebral Folate deficiency & Ranges; Autistic Phenotypes: Language, Communication, & Behaviors40:45 Language & Communication; Self-Injurious Behaviors; Hyperactivity, Agitation; Treatment duration42:53 Folate Autoantibodies & Maternal Health & Markers45:30 Studies & Behavioral outcomes; inflammation & thyroid findings46:58 Neural development; Language connections, white matter tracts & distal connections48:53 Leucovorin for different severity/levels of Autism; Spinal Bifida51:08 Preparing for pregnancy53:50 Transgenerational aspects of Folate Autoantibodies Research; Prenatal Care & Awareness59:32 Guidance & SupportX: https://x.com/rps47586Hopp: https://www.hopp.bio/fromthespectrumYT: https://www.youtube.com/channel/UCGxEzLKXkjppo3nqmpXpzuAemail: info.fromthespectrum@gmail.com

Lucy and Ellie chat about large language models, chat interfaces, and causal inference. Do LLMs Act as Repositories of Causal Knowledge?: https://arxiv.org/html/2412.10635v1 Follow along on Twitter: The American Journal of Epidemiology: @AmJEpi Ellie: @EpiEllie Lucy: @LucyStats

This episode is sponsored by: Set For LifeSet for Life Insurance helps doctors safeguard their future with True Own Occupational Disability Insurance. A single injury or illness can change everything, but the best physicians plan ahead. Protect your income and secure your future before life makes the choice for you. Your career deserves protection—act now at https://www.doctorpodcastnetwork.co/setforlife_____Burnout and distress are pervasive in medicine, but improving physician well-being requires more than just resilience training and pizza parties. In this episode, Dr. Colin West shares the latest research on physician burnout, highlighting how workplace culture significantly impacts well-being. He and Dr. Bradley Block discuss the flawed "just tough it out" mindset ingrained in medical training, the systemic factors that contribute to distress, and the importance of aligning work with meaning, values, and purpose (MVPs) to maintain fulfillment in a medical career.They also explore practical solutions for physicians in various practice settings, from small groups to large institutions, emphasizing how addressing inefficiencies and reducing administrative burdens can enhance both job satisfaction and patient care. The conversation covers the role of coaching, social connection, and leadership in fostering a healthier medical culture, offering valuable insights for individual physicians and healthcare leaders alike..Three Actionable Takeaways:Burnout is not an individual problem—it's systemic: While personal coping strategies help, real change requires addressing workplace inefficiencies, excessive administrative burdens, and leadership approaches.Well-being initiatives must go beyond surface-level fixes: Yoga and mindfulness have value, but true solutions require structural changes like reducing unnecessary tasks and fostering social connections.Investing in physician well-being benefits everyone: When doctors are supported, they perform better, stay in their jobs longer, and deliver higher-quality patient care. About the Show:The Physician's Guide to Doctoring covers patient interactions, burnout, career growth, personal finance, and more. If you're tired of dull medical lectures, tune in for the real-world lessons we should have learned in med school!About the Guest:Dr. Colin P. West is a Professor of Medicine, Medical Education, and Biostatistics at Mayo Clinic, specializing in internal medicine. He earned his M.D. and Ph.D. in Biostatistics from the University of Iowa. Dr. West's research focuses on physician well-being, burnout, and evidence-based medicine. He has published over 200 peer-reviewed articles and co-chaired the 2019 National Academy of Medicine consensus study on clinician burnout.Website: https://www.mayo.edu/research/faculty/west-colin-p-m-d-ph-d/bio-00027800LinkedIn: https://www.linkedin.com/in/colin-west-57821b82/About the Host:Dr. Bradley Block is a board-certified otolaryngologist at ENT and Allergy Associates in Garden City, NY. He specializes in adult and pediatric ENT with interests in sinusitis and obstructive sleep apnea. Dr. Block also hosts the Physician's Guide to Doctoring podcast, focusing on personal and professional development for physicians.Want to be a guest? Email Brad at brad@physiciansguidetodoctoring.com or visit www.physiciansguidetodoctoring.com to learn more!Socials:  @physiciansguidetodoctoring on Facebook  @physicianguidetodoctoring on YouTube  @physiciansguide on Instagram and Twitter Visit www.physiciansguidetodoctoring.com to connect, dive deeper, and keep the conversation going. Let's grow! Disclaimer:This podcast is for informational purposes only and is not a substitute for professional medical, financial, or legal advice. Always consult a qualified professional for personalized guidance.

Lisa LaVange is the 2018 President of the American Statistical Association and she is PhD, is Professor and Associate Chair of the Department of Biostatistics { add link to dept } in the Gillings School of Global Public Health { add link to Gillings SPH } at the University of North Carolina at Chapel Hill. She is also director of the department's Collaborative Studies Coordinating Center (CSCC), overseeing faculty, staff, and students involved in large-scale clinical trials and epidemiological studies coordinated by the center. Ronald L. (Ron) Wasserstein is the executive director of the American Statistical Association (ASA). Wasserstein assumed the ASA's top staff leadership post in August 2007. Prior to joining the ASA, Wasserstein was a mathematics and statistics department faculty member and administrator at Washburn University in Topeka, Kan., from 1984–2007. During his last seven years at the school, he served as the university's vice president for academic affairs.

In a recent episode of Oncology on the Go, several oncologists discussed the impact of the COVID-19 pandemic on oncology care, 5 years later. Each doctor discussed a different aspect of multidisciplinary care, including medical oncology, radiation oncology, and epidemiology. CancerNetwork® spoke with leading clinicians including:  ·      Aditya Bardia, MD, MPH, FSCO, professor in the Department of Medicine, Division of Hematology/Oncology, and director of Translational Research Integration at the University of California Los Angeles Health Jonsson Comprehensive Cancer Center; ·      Ritu Salani, MD, director of Gynecologic Oncology at the University of California Los Angeles, and ONCOLOGY® editorial advisory board member; ·      Scarlett Lin Gomez, PhD, MPH, a professor in the Department of Epidemiology and Biostatistics at the University of California San Francisco (UCSF), and co-leader of the Cancer Control Program at UCSF Helen Diller Family Comprehensive Cancer Center ·      Marwan F. Fakih, MD, professor in the Department of Medical Oncology & Therapeutics Research, associate director for Clinical Sciences, medical director of the Briskin Center for Clinical Research, division chief of GI Medical Oncology, and co-director of the Gastrointestinal Cancer Program at City of Hope Comprehensive Cancer Center; ·      Elizabeth Zhang-Velten, MD, a radiation oncologist at Keck Medicine of University of Southern California;  ·      Frances Elain Chow, MD, neuro-oncologist at the University of Southern California (USC) Norris Comprehensive Cancer Center ·      James Yu, MD, MHS, FASTRO, assistant professor adjunct, Department of Radiation Oncology, Smilow Cancer Hospital at Saint Francis Hospital, and ONCOLOGY® editorial advisory board member.  The COVID-19 pandemic disrupted routine cancer care in a number of ways. Many patients were unable to receive timely screening, diagnosis, and treatment, Fakih noted. Additionally, Bardia stated that the pandemic led to a decrease in the number of patients participating in clinical trials. One of the most significant changes in oncology care, according to Salani, has been the increased use of telehealth. Telehealth has allowed patients to receive care from the comfort of their own homes, which has been especially beneficial for patients who live in rural areas or who have difficulty traveling. Telehealth has also made it easier for patients to connect with their doctors and to receive support from other members of their care team.  For Gomez, the COVID-19 pandemic also highlighted the importance of addressing the structural and social drivers of health. These are the conditions in which people are born, grow, live, work, and age that can affect their health. For example, people who live in poverty or who lack access to healthy food are more likely to develop cancer. The pandemic has led to a renewed focus on addressing these disparities. Overall, the COVID-19 pandemic has had a profound impact on oncology care. However, it has also led to a number of positive changes, such as the increased use of telehealth and the focus on addressing the structural and social drivers of health. In the years to come, it will be important to continue to build on these changes in order to improve the lives of patients with cancer.

Welcome to Episode 245 of Autism Parenting Secrets. In this episode of Autism Parenting Secrets, we're joined by Dr. Richard Frye, a renowned child neurologist specializing in neurodevelopmental disorders, to explore the critical medical insights that can help children with autism thrive. Dr. Frye shares his expertise on mitochondrial dysfunction, immune system dysregulation, and other underlying medical issues affecting autism. We discuss the importance of evidence-based treatments, foundational aspects like sleep and gut health, and the significance of a tailored approach to each child's unique needs. Join us as we delve into the strategies and emerging interventions that offer the most promise for helping children with autism live their best lives.The secret this week is... EVIDENCE-BASED Treatments FIRSTYou'll Discover:Two Connected Challenges to Tackle Early in the Journey (4:15)Signs of Poor Gut Health (11:29)Three Key Issues You Can Measure and Treat (19:58)Why Mitochondria Matter So Much (22:49)The Importance of Folate Metabolism (25:35)Why Less Is MORE (34:43)About Our Guest:Dr Frye is a Child Neurologist with expertise in neurodevelopmental and neurometabolic disorders. He received an MD and PhD in Physiology and Biophysics from Georgetown University.  He completed a residency in Pediatrics at the University of Miami, Residency in Child Neurology and Fellowship in Behavioral Neurology and Learning Disabilities at Harvard University/Children's Hospital Boston, and Fellowship in Psychology at Boston University.  He also received a Master's in Biomedical Science and Biostatistics from Drexel University. He holds board certifications in Pediatrics and Neurology with Special Competence in Child Neurology.  He has authored over 300 publications and book chapters and serves on several editorial boards.Dr. Frye is a national leader in autism spectrum disorder (ASD) research. He is President and Chief Scientific Officer of the Autism Discovery and Treatment Foundation, Chief Medical Officer of the Neurological Health Foundation, Director of Research and Neurologist at the Rossignol Medical Center, and Principal Investigator at the Southwest Autism Research and Resource Center.He has led several clinical studies on children with ASD, including studies focusing on defining the clinical, behavioral, cognitive, genetic, and metabolic characteristics of children with ASD and mitochondrial disease and several clinical trials demonstrating the efficacy of safe and novel treatments that target underlying physiological abnormalities in children with ASD, including studies on leucovorin, cobalamin and tetrahydrobiopterin and has an ongoing multicenter controlled clinical trial on leucovorin, neuroimmune modulators and photobiomodulation.https://drfryemdphd.com/References in The Episode:Medical Academy of Pediatrics & Special Needs MAPSAdditional Resources:Unlock the power of personalized 1-on-1 support, visit allinparentcoaching.com/intensiveTake The Quiz: What's YOUR Top Autism Parenting Blindspot?To learn more about Cass & Len, visit us at www.autismparentingsecrets.comBe sure to follow Cass & Len on InstagramIf you enjoyed this episode, share it with your friends.

Welcome to another episode of The Effective Statistician! Today, I sit down with Darko Medin to explore how artificial intelligence is transforming biostatistics. Darko works as a biostatistician for companies worldwide and builds digital solutions that push AI's boundaries. We dive into Bio AI Works, the platform he's developing to improve AI reliability and eliminate issues like hallucinations in large language models. Darko explains how AI can enhance statistical accuracy, uncover hidden data patterns, and accelerate breakthroughs in oncology and precision medicine. If you want to understand how AI can revolutionize biostatistics while maintaining scientific rigor, this episode is for you. Let's get started!

Title: Episode 6- Hypothesis Testing (e.g. Type 1 and Type II Errors, P-values) Target Audience This activity is directed to physicians who take care of hospitalized children, medical students, nurse practitioners, and physician assistants working in the emergency room, intensive care unit, or hospital wards. Objectives: Upon completion of this activity, participants should be able to: 1.      Discuss the definition and relevance of p-values. 2.      Discuss type 1 vs type ii errors. 3.      Discuss statistical significance and what it means.   Course Directors: Tony R. Tarchichi MD — Associate Professor, Department of Pediatrics, Children's Hospital of Pittsburgh of the University of Pittsburgh Medical Center (UPMC.) Paul C. Gaffney Division of Pediatric Hospital Medicine. No relationships with industry relevant to the content of this educational activity have been disclosed. Jenna Carlson Ph.D. - University of Pittsburgh- Assistant Professor of Human Genetics and Biostatistics in school of Public Health No relationships with industry relevant to the content of this educational activity have been disclosed. Conflict of Interest Disclosure: No other planners, members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose. Accreditation Statement: In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.  The University of Pittsburgh School of Medicine designates this enduring material activity for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.   Disclaimer Statement: The information presented at this activity represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the UPMC Center for Continuing Education in the Health Sciences, UPMC / University of Pittsburgh Medical Center or Affiliates and University of Pittsburgh School of Medicine.  Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses. Released 2/20/2025,  Expires 2/20/2028 The direct link to the course is provided below: https://cme.hs.pitt.edu/ISER/app/learner/loadModule?moduleId=25580&dev=true

The rise of multiple sclerosis (MS) registries worldwide has transformed MS research, providing access to vast clinical data spanning years. This development also triggers critical conversations about how best to use real-world data to answer questions over the treatment of people with MS and the potential shift towards personalised medicine. In this episode, guests Professor Tomas Kalincik, Head of the Clinical Outcomes Research (CORe) Unit at the University of Melbourne and the MS Centre at the Royal Melbourne Hospital in Australia, and Maria Pia Sormani, Professor of Biostatistics at the University of Genoa in Italy, share their expert insights on harnessing real-world data with host Brett Drummond of MStranslate.

You can text us here with any comments, questions, or thoughts!In our latest episode, Kemi sit down with Dr. Sharon Onguti, an infectious diseases specialist at Vanderbilt University Medical Center, where she has served since 2022. Board-certified in Internal Medicine and Infectious Diseases, she completed her fellowship at UT Health San Antonio and a sub-fellowship in Antimicrobial Stewardship at Stanford University. Dr. Onguti holds an MPH in Epidemiology and Biostatistics from Johns Hopkins Bloomberg School of Public Health and is a board member of the Society of Bedside Medicine, she is dedicated to medical education and serves as Associate Program Director of the Infectious Diseases Fellowship Program. She is also is an alumnus of our Get That Grant® coaching program! Join the conversation as Dr. Onguti shares her remarkable journey in medicine, highlighting her innovative use of AI in healthcare. Highlights: Discover how she navigates multiple roles and responsibilities while finding clarity and focus through coaching.  The importance of aligning your career with personal values and interests.  Why regular reflection and inventory of your activities help ensure alignment with long-term goals. Insights on cultivating a high-functioning support network and redefining mentorship to propel your career forward. Loved this convo? Please go find Dr. Onguti on LinkedIn and Twitter/X show her some love!  If you'd like to learn more foundational career navigation concepts for women of color in academic medicine and public health, sign up for our KD Coaching Foundations Series: www.kemidoll.com/foundations. And if you're also a high-achieving WOC facing these challenges and seeking to navigate your path more effectively, Get That Grant is here to support you! Join the waitlist for our April 2025 Get That Grant cohort! Enrollment for the April cohort is exclusive to our waitlist, so sign up now to take the first step toward turning your aspirations into reality. Applications will be sent directly to the waitlist on Monday, February 17.  Sign up for the waitlist now at  www.kemidoll.com/gtgwaitlist REMINDER: Your Unapologetic Career Podcast now releases episode every other week! Can't wait that long? Be sure you are signed up for our newsletter (above) where there are NEW issues every month! 

On the newest episode of Cyberology, Dr. Luke Chowning, assistant professor in the College of Education & Human Performance, talks about exercise science, biomechanics, biostatistics, and how technology is elevating it all. Starting with a broad explanation of exercise science, the body's response to exercise, down to the mechanical assessment of specific movements, muscles, or tissues in the execution of movement. Hosted on Acast. See acast.com/privacy for more information.

Title: Episode 2- Study Design, Performance, Analysis and Generalizability Target Audience This activity is directed to physicians who take care of hospitalized children, medical students, nurse practitioners, and physician assistants working in the emergency room, intensive care unit, or hospital wards. Objectives: Upon completion of this activity, participants should be able to: Review Study design. Review Performance and analysis. Review generalizability vs internal validity.   Course Directors: Tony R. Tarchichi MD — Associate Professor, Department of Pediatrics, Children's Hospital of Pittsburgh of the University of Pittsburgh Medical Center (UPMC.) Paul C. Gaffney Division of Pediatric Hospital Medicine. Jenna Carlson Ph.D. - University of Pittsburgh- Assistant Professor of Human Genetics and Biostatistics in school of Public Health Rebekah Miller MLIS - University of Pittsburgh School of Medicine - Research & Instruction Librarian Conflict of Interest Disclosure: No other planners, members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose. Accreditation Statement: In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.  The University of Pittsburgh School of Medicine designates this enduring material activity for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.   Disclaimer Statement: The information presented at this activity represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the UPMC Center for Continuing Education in the Health Sciences, UPMC / University of Pittsburgh Medical Center or Affiliates and University of Pittsburgh School of Medicine.  Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses. Released 1/23/2025,  Expires 1/23/2028 The direct link to the course is provided below:

In this episode Dr. Ted O'Connell breaks down Biostatistics questions 13, 14, and 15 from our online question bank. Our Websites MedPrepToGo Website BookRevision.com Dr. O'Connell's Website Dr. Dasgupta's Website Other Podcasts USMLE Step 1 Ad-Free Bundle Crush Step 1 Step 2 Secrets Beyond the Pearls The Dr. Raj Podcast Beyond the Pearls Premium USMLE Step 3 Review Dr. Ted O'Connell Dr. O'Connell is the Founding Program Director of the Family Medicine Residency Training Program at Kaiser Permanente Napa-Solano and Chief of the Department of Family and Community Medicine at Kaiser Permanente Vallejo. He is an Associate Clinical Professor in the Department of Family and Community Medicine at the UC San Francisco School of Medicine and an Associate Clinical Professor in the Department of Family Medicine at the UC Davis School of Medicine. Dr. O'Connell has previously been on the teaching staff at the UCLA and Drexel University Schools of Medicine. Dr. Raj Dasgupta Dr. Dasgupta is an ABIM Quadruple board-certified physician specializing in internal medicine, pulmonology, critical care, and sleep medicine. He practices at the University of Southern California, where he is an associate professor of clinical medicine, assistant program director of the Internal Medicine Residency Program, and the associate program director of the Sleep Medicine Fellowship. Dr. Dasgupta is an active clinical researcher and has been teaching around the world for more than 18 years. Legal/Credits All information is for entertainment and educational purposes only and is not intended as medical advice. Produced by: Christopher Breitigan Intro/Outro music: "Digital Journey" by Tim Beek (timbeek.com) Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode we speak with Wenqing (Sienna) Zhang (MPH '17), a trailblazer in public health and global healthcare innovation. Sienna shares how her passion for medical technology led her from studying pharmaceutical sciences to pursuing a master's in biostatistics and epidemiology at NYU. She recounts pivotal experiences, including internships at Pfizer and the NYC Department of Health, her role at Medtronic's first innovation accelerator in China, and her current work at Illumina, where she is driving advancements in gene sequencing worldwide. A Forbes 30 Under 30 honoree, Sienna offers candid insights into her cross-cultural career, her strategies for connecting innovation with business, and how she overcame challenges to lead in multinational settings. To learn more about the NYU School of Global Public Health, and how our innovative programs are training the next generation of public health leaders, visit http://www.publichealth.nyu.edu.

Send us a textYou've heard the phrase, “Sitting is the new smoking,” but is it really true—or just an oversimplification? And do standing desks at work actually improve your health? In this episode of Causes or Cures, Dr. Eeks chats with Dr. Bethany Barone Gibbs about her recent study on standing desks and their surprising effects on blood pressure, a key indicator of health. Dr. Gibbs explains how the study was conducted, what the outcome measures revealed, the unexpected findings, and her recommendations for the broader public. Plus, she shares her expert take on whether “sitting is the new smoking” holds up to scientific scrutiny.Dr. Bethany Gibbs is the chair and professor of the Department of Epidemiology and Biostatistics at West Virginia University School of Public Health. Her research focuses on cardiovascular and physical activity epidemiology, as well as lifestyle interventions to prevent heart disease. Learn more about her work here.So, before you fully commit to a standing desk, tune in to hear what the science really says about the workplace wellness trend!You can contact Dr. Eeks at bloomingwellness.com.Follow Eeks on Instagram here.Or Facebook here.Or X.On Youtube.Or TikTok.SUBSCRIBE to her monthly newsletter here.Support the show

Deans chat welcomes Dr. George Tye Liu, current president of the American College of Foot and Ankle surgeons! Dr. Liu is a remarkable leader of the profession, currently working in Dallas TX as an Associate Professor in the Department of Orthopedic Surgery at University of Texas Southwestern. Dr. Liu specializes in Foot and Ankle Trauma and Reconstruction surgery. He completed his undergraduate degree from Trinity University in San Antonio TX with a double major in Biochemistry and Biology. Join us, as we get the inside scoop into what sparked his interests in podiatric medicine. He went on to complete his 4 yr podiatric medical degree with Temple University followed by his 3 year surgical residency program with University of Texas Health Science Center. As a lifelong learner, Dr. Liu completed additional Fellowship training with 2 international fellowships focused on Orthopedic Trauma, one in Dresden, Germany with AO and the other in Catania, Italy. Tune in, as he describes how Fellowship training influenced and impacted his career.  Dr. Liu is also a prolific educator. He has authored over 50 peer-reviewed articles, delivered a plethora of invited lectures both nationally and internationally as well authored many textbook chapters in the topics of foot and ankle surgery. Listen, as he shares some of his experiences education during multi-disciplinary grand rounds with orthopedic, internal medicine, radiology and podiatric residents at University of Texas Southwestern.  As a section editor for the Journal of Foot and Ankle surgery, Dr. Liu shares his insights about publishing and conducting research. He recently obtained his Masters degree in Biostatistics from the University of Nebraska Medical Center. Listen, as he shares why high quality research is important to advance the future of foot and ankle surgery and the podiatric profession in general.  Dr. Liu has been a tremendous leader in the profession both nationally and locally. He has received many awards in his career and describes how the call of leadership drives us forward. He has served in many roles (chair, board member and committee member for various task forces) with the Texas Podiatric Medical Association. He is current faculty for the AO North America, prior chair of Planning committee for the American Diabetes Association and part of the Advisory board for the American Academy of Foot and Ankle Osteosynthesis. We hope you enjoy this opportunity to get to know Dr. George Tye Liu!  https://www.acfas.org/ https://www.abfas.org/residents https://www.aofoundation.org/aona https://utswmed.org/doctors/george-liu/  

This piece was recorded at the The 7th Collaborative Clinical Trials in Anaesthesiology Conference, Prato, Italy. The discussion centers around the roles and contributions of bio statisticians in clinical trials. Presented by Kate Leslie and Andy Cumpstey with their guests, Jessica Kasza, Professor of Biostatistics, Data Analytics/Modelling and Health Economics at Monash University and Elizabeth Ryan, Research Fellow at Monash University.

Have you ever wondered when it might be time to leave your job? Or how to keep repeating the same mistakes at work? Set yourself up for success? Make your voice heard? Create a healthy workplace for your team/employees? This episode is the virtual launch party for the "Millennials' Workbook for Navigating Workplace Politics" where we'll interview the co-authors, get a sneak peek into their framework and process, challenges for writing about these topics, and activities the audience can try right after listening. Have you just graduated from school and are entering the workforce for the first time? Are you a millennial who has a tough time gelling with older generations of coworkers? Are you interested in leveling-up at work, having your voice heard, or moving into a leadership position? In this episode, Dr. Brancu, the host of the Hard Skills talks with her co-authors of the Millennials Workbook for Navigating Workplace Politics about how the workbook can help put into practice the principles outlined in their original guide published in 2021 (Millennials Guide to Workplace Politics). The episode will also be their virtual launch party since the book comes out on this air date! We'll offer a sneak peek into talk what led to writing this workbook, how long it took, hiccups along the way, challenging decision points, and do a brief reading with several activities! Sarah A. Rose is a project manager and consultant with 15 years of experience working for nonprofit organizations aiming to improve quality of life through education and science. Upon entering the workforce, Sarah struggled to reconcile her multiple identities in corporate America. During her tenure at the American Psychological Association, she was offered numerous personal and professional opportunities, one of which is co-authoring this book. Sarah executes her work through a lens of diversity, equity, and inclusion. This stems from her multicultural and bilingual upbringing as a German-American in a military family. She graduated with bachelor's degrees in psychology and international studies. Sarah lives in Germany with her twin cats, Berlioz and Toulouse. Dr. Jennifer Wisdom is a licensed clinical psychologist and board-certified organizational psychologist. She is principal of Wisdom Consulting, a Senior Organization Development Psychologist with the Veterans Health Administration's National Center for Organization Development, and an Affiliated Professor at the Oregon Health and Science University. She has published and taught extensively on leadership and public health, including authoring the Millennials' Guides series. She has a PhD in Clinical Psychology and a Master's of Public Health in Biostatistics and Epidemiology.***IF YOU ENJOYED THIS EPISODE, CAN I ASK A FAVOR?We do not receive any funding or sponsorship for this podcast. If you learned something and feel others could also benefit, please leave a positive review. Every review helps amplify our work and visibility. This is especially helpful for small women-owned boot-strapped businesses. Simply go to the bottom of the Apple Podcast page to enter a review. Thank you!***LINKS MENTIONED IN EPISODE:Guest sites: https://www.linkedin.com/in/sarsonderhttps://www.linkedin.com/in/jenniferpeltwisdom/https://www.leadwithwisdom.com/booksBook series on Amazon: https://www.amazon.com/dp/B0CNRBP81H?binding=kindle_edition&searchxofy=true&ref_=dbs_s_aps_series_rwt_tkin&qid=1732221877&sr=8-1Our website: www.gotowerscope.com

Editor-in-Chief Dr. Sue Yom hosts Dr. Mai Anh Huynh, Assistant Professor of Radiation Oncology at the Brigham and Women's Hospital / Dana-Farber Cancer Center who wrote an editorial this month, "The Hidden Benefits of Palliative Radiotherapy: When Radiation of Metastatic Disease is Not "Just" Palliative," Dr. David Palma, a Radiation Oncologist at the London Health Sciences Centre who co-authored, "Ablative Radiation Therapy to Restrain Everything Safely Treatable (ARREST): A Phase I Study of Stereotactic Ablative Radiotherapy for Poly-metastatic Disease", and Dr. Ethan Ludmir, Assistant Professor in the Departments of Gastrointestinal Radiation Oncology and Biostatistics at the University of Texas MD Anderson Cancer Center and supervising author of "Off-Protocol Radiotherapy in Phase III Metastatic Solid Tumor Trials." The group also discusses an article from this month's issue, "Is Local Ablative Stereotactic Radiation Therapy a Valuable Rescue Strategy for Time on Drug in Patients Enrolled in Phase I Trials?"

Host Dr. Davide Soldato and Dr. Aaron Mitchell discuss the JCO article "Quality of Treatment Selection for Medicare Beneficiaries With Cancer" TRANSCRIPT Dr. Davide Soldato: Hello and welcome to JCO After Hours, the podcast where we sit down with authors from some of the latest articles published in the Journal of Clinical Oncology. I am your host, Dr. Davide Soldato, medical oncologist at Hospital San Martino in Genoa, Italy. Today, we are joined by JCO author Dr. Aaron Mitchell. Dr. Mitchell is a medical oncologist working at Memorial Sloan Kettering Cancer Center where he is also part of the Department of Epidemiology and Biostatistics. Dr. Mitchell specializes in treating genitourinary malignancy and has a research focus on improving how the healthcare system helps people with these and other cancers. So today, Dr. Mitchell will be discussing the article titled, “Quality of Treatment Selection for Medicare Beneficiaries with Cancer.” Thank you for speaking with us, Dr. Mitchell. Dr. Aaron Mitchell: Well, thank you for inviting me. I'm very glad to be here. Dr. Davide Soldato: So I just wanted to introduce the topic by asking a couple of questions, very general, about the background of the article. So basically you reported the data using the SEER-Medicare to assist to assess the determinants of optimal systemic therapies delivery and selection. So, in particular, you focused on individuals that were diagnosed with cancer who were Medicare beneficiaries and in particular were part of the low income subsidy, which is also known as LIS. So I just wanted to ask you if you could briefly explain to our listeners how this program works, and what was the rationale of the study, and if there is any element of novelty in your study compared to what was done before the study was published. Dr. Aaron Mitchell: Yeah. So that's a lot to cover, but yeah, a lot of opportunity to introduce the low income subsidy program which is a very important part of the Medicare program for prescription drugs, but often one that flies under the radar a little bit in the policy discussion. So this subsidy was created synchronously back with the Medicare Part D Program, which was created in 2006. There was some anticipation that for some high cost drugs, not all patients would be able to afford them even with the Part D program insurance as it was being created. And so they created a pathway to give an additional subsidy to some patients who had low income, who were anticipated to being at need and needing that assistance to afford high cost drugs. As the number of high cost drugs has really risen since 2006, this program has played an important role in helping patients afford drugs, especially those who need very expensive cancer drugs.  And what this program does is, once you meet the eligibility requirements, which require patients to have both quite a low income. So if you're single, that is at 135% of the federal poverty limit or below, and it also places some restrictions on assets. You also have to have low assets, so low income and low assets in order to qualify for the subsidy. But then once you do, the subsidy is really quite large. Patients who qualify for the LIS at the full subsidy level will pay about $10 per month per drug, even for specialty cancer drugs. So if you think about drugs such as those that we use to treat prostate cancer, my specialty, drugs like enzalutamide or XTANDI that run $15,000 to $20,000 per month, the out of pocket cost for a low income subsidy beneficiary is $10. So that is a huge discount. $10 isn't nothing, but even for someone with a low income, if they've got one or two cancer drugs that are at this rate, it's something that they can often afford.  This program applies to Part D cancer drugs that are prescription drugs basically. By and large, these are oral pills that patients are taking on a daily basis at home. These are the drugs that the low income subsidy program applies to. So if a patient needs a drug like that to treat their cancer, then they are able to receive it at very low cost. And what you'll see is a patient- in the studies that have been done, when a patient has low income, low enough for them to be able to qualify for this program, they then have better access to these drugs. You see increased adherence rates, you see increased prescription fill rates. And then when someone, when their income is just high enough to no longer qualify for this program, and they go back to regular Medicare Part D coverage, that's when the problems arise. So it's like as your income moves up the scale, you actually get more problems affording your cancer drugs. So that's the state of the literature so far.  And what we realize though, is that all these studies that have looked at the low income subsidy have really focused on just the Part D drugs themselves, the oral drugs. And that's certainly not all of cancer care. There is a growing number of oral drugs, but for many cancers, especially when you're talking about immunotherapy drugs or new systemic radioligand therapies, these are not Part D drugs, these are Part B drugs. And so even if you are low income and you're qualifying for this subsidy, it's not going to help you if you need a Part B drug. Yes, there are certainly a whole host of other programs and different avenues that we can get patients assistance, but some percentage of them, even though they're low income and high need, would not have assistance with a Part B drug.  So now, in coming back, the long answer to your question, our rationale was, let's look at these Part D low income subsidy patients and let's see what their access looks like, not just to the oral drugs, but to cancer care writ large. And can we study where they're fitting into the system, not only when they need oral drugs, but when they need any kind of cancer care across the board? Dr. Davide Soldato: So basically, just to summarize, it was an extension of previous literature, but specifically evaluating whether novel regimens that use, for example intravenous drugs, they were covered at the same level and whether there were any inequities in access to cancer treatment under this specific program, which is the LIS. Dr. Aaron Mitchell: Yes, I'd say that's a fair summary. Dr. Davide Soldato: Okay. So more or less, you included 9,000 patients inside of the study and 25% of them were beneficiaries of the LIS program. And you specifically looked at factors that could be associated with not receiving therapies at all, and also whether the quality of care that these patients were receiving were any different compared to those who were not part of the LIS program. So I just wanted to see if you could guide us a little bit in the results, whether you see any kind of differences when we look at access to any type of systemic therapies and whether being a part of the LIS program modified access to the drugs. Dr. Aaron Mitchell: Let me take this opportunity also to highlight a feature of our study that differentiates us a little bit from previous work that's been done. And this is around the specific definition of quality that we use. I know quality is in the title of the manuscript, but I think it's important to emphasize exactly what we mean in this study when we say quality, and it's something very specific. So our measure of quality references back to the NCCN guidelines, which I don't think our audience needs much of an introduction to that. It's the most worldwide recognized standard of care guidelines for oncology practice. And we specifically looked not only at the NCCN guidelines, but at their evidence block scoring system. So what we did was we looked not only at one set of guidelines, but we looked at guidelines across time. We looked at guidelines across our full study period, which was, give or take, 2015-2018, depending on the cancer. And we looked at each point in time to see what was the treatment regimen that was recommended by the NCCN guidelines as being preferred. Some of them make that designation, some of them don't. If there was not a designation of preferred, then we turned to the evidence blocks. And the evidence blocks, we then apply several different measures to kind of rank treatments from those that get high scores for efficacy and safety to those that get low scores for efficacy, safety and the quality of evidence. So we basically come up with a kind of a rank list of the recommended treatments at each point in time. And then we look at the ones that are the highest, we say which are the most highly recommended treatments at any given point in time. That then becomes our definition of quality treatment. And I'm saying this with air quotes, we use the term “optimal treatment” in the study. Did they get that treatment? If there were ties, you could have gotten either of the two treatments that got the equally good score, did you get that treatment versus did you get anything else?  So then getting back to our analysis, what we really did was kind of a two-stage study. First, we put all of our patients into our pool, into one big analytic model. And we looked to see what are the factors that predict or are associated with a patient either getting no systemic therapy or any systemic therapy. And then as a second question, we look at the patients who got some form of systemic therapy, and then we ask, again, what percentage of those got the optimal treatment or high quality treatment as opposed to one of the more lowly recommended treatment regimens? So that's how we asked it. We found that patients who were low income subsidy recipients, the low income ones, they were both less likely to receive any systemic therapy. And then even the ones that receive systemic therapy, the ones who made it in the door to see their doctor or their part of the system, they still were less likely to get the optimal treatment that was recommended for their cancer type at the time that they were diagnosed. Dr. Davide Soldato: So basically, even when you are a part of this subsidiary program, you still have a lower access to any type of treatment. And even if you get treatment, you kind of get the ones that were not the preferred according to the NCCN guidelines, or at least they were not scoring as well as those specific regimens. But I think that what our audience might be wondering about is that frequently there are also some other types of characteristics, for example, age or number of comorbidities, which can be associated with having a low socioeconomic status. So I was wondering whether in the analysis you kind of looked specifically also at patient factors, for example, income rather than age or comorbidities, and whether you found any significant association with those and whether it was something that you planned to do in your study. Dr. Aaron Mitchell: Yes. So we looked at many patient factors and those included age and they included the degree of comorbidity. And what we saw with respect to those characteristics was not too surprising. We saw that patients who were older were less likely to receive systemic therapy. We saw that patients who had more comorbidities were also less likely to get systemic therapy. And then across our different designations of treatments, we saw that those patients were also less likely to get the optimal treatment for their cancer. This result though, we would say it certainly needs more study in the future, but it's not immediately concerning. And that is because for patients who have more age, more comorbidity, those often correlate with frailty. And so it could be that these patients aren't getting optimally treated or it could be that their oncologists are just making clinically appropriate decisions about patient selection.  We saw as we were doing this work that the treatment regimens that are often getting the highest recommendations from the NCCN, hence, it would become our definition of high quality optimal treatment, are often ones that are aggressive. They're often ones that are multi-drug combinations. They're often ones that it's not just your old antineoplastics, it's the antineoplastics plus an additional immunotherapy or plus a targeted drug. So it's the ones that are more aggressive by and large, and that might be in some cases more than a patient who is older, more frail, could be able to tolerate. And so the oncologist might be making inappropriate judgment to say I'm going to do something a little bit less aggressive here and make an appropriate trade off between anti cancer efficacy and safety.  I think we've got kind of a bookmark there and we can look at those trends in the future. So we saw that kind of as expected, and then we turned and looked towards the low income subsidy. And our premise there is, well, your income shouldn't predict what you're getting clinically. In an ideal world, you'd be able to get the appropriate treatment for a patient, and not depend on whether their income is above or below 135% of the poverty limit. So that one seems more like on its face an immediate concern. Dr. Davide Soldato: Thank you very much for the explanation. I was just wondering, did you make some kind of selection when you were analyzing specific diseases or settings where you included just metastatic patients or you also included patients with early stage neoadjuvant treatments? Because I think that it is also very interesting from the perspective of the objectives that we have as oncologists when we are administering systemic treatments. Dr. Aaron Mitchell: Yeah, thank you for bringing that up. That was also one of the goals of our study was to be broad. And we wanted to look for factors, whether it be low income subsidy, whether it be age, socioeconomic background, etc., things that would be broad predictors of outcomes, and by which I mean care delivery outcomes across the board. So not just for, let's say, metastatic breast cancer, but also across any cancer that a patient might walk in the door with, what are the systemic predictors. And so when you mentioned before that our overall cohort is approximately 9,000 patients, that's 9,000 patients split over a variety of what we call clinical scenarios or clinical indications. And that includes multiple solid tumor as well as liquid tumor malignancies. It includes both patients who are initiating systemic therapy with palliative intent for metastatic disease. It also includes several groups of patients who are getting adjuvant therapy. So we want it to be as broad as possible. Our selection of those scenarios was really done with the goal of being as broad as possible and really bringing in everything that we could within the constraints of our data source. And that was really the only limitation that we applied in concept was tumor types that are common enough to have a meaningful sample of patients to analyze. So, one, are there enough patients? And then two, are you able to identify this specific group of patients within SEER-Medicare data? Because when the NCCN divides groups of patients by biomarkers that are not available in SEER-Medicare, we can't really say, “Oh, we're going to study this group of patients.” That would then be one that we have to leave on the side and not include. But everything else where one of those things didn't apply, we tried to include it as best we could. Dr. Davide Soldato: Thank you very much for the explanation. And among the scenarios that you included in the study, were there any striking differences in terms of access to treatment and access to quality treatment the way you define the study? Dr. Aaron Mitchell: Yes, there were differences between these different cancer types, these different cancer indications, but they're not differences that I want to over interpret or read too much into. Certainly, every cancer indication is going to be different, but when we start getting into the individual cancer types, the sample size does get smaller. And we've not done formal tests of comparison or heterogeneity among cancer types. So I don't want to say that the differences which we certainly do see, like numerically, there are differences in the proportion of patients who are getting optimal treatment versus no treatment. I don't want to say that it's because the low income subsidy status or patient age has a bigger impact, let's say for lung cancer than breast cancer. I want to say that is heterogeneity for potential future study when we are able to do a similar follow up analysis with say a larger sample size. I don't want to over interpret those differences at the moment. Dr. Davide Soldato: I was just wondering in case there was anything in particular that you wanted to highlight. But in the end, I think that we also have to acknowledge that the data are based on claims data, observational data. So maybe you're right when you say we should not over interpret this type of difference.  And this is just to speculate a little bit, do you think that if you would look at this same specific question in a more contemporary diagnosis frame, like for example, you refer to the fact that most of the diagnoses were between 2016 and 2018. Now that we have more and more of these drugs that would qualify as Part B in the adjuvant or new adjuvant setting, do you think that you would see more differences compared to what you observed in the current study or do you think that it would be more or less the same? Of course this was not part of the analysis that you did, but it's just to have your opinion on the topic in general. Dr. Aaron Mitchell: My expectation would be that since not much has changed with respect to the low income subsidy program from the time period of our study until now, my baseline expectation would be that those results would hold. On the other hand, it is the case that there have been improvements to the standard Medicare Part D benefit since the time of our study. So the low income subsidy patients would be paying the same low out of pocket costs that I mentioned before, about $10 a month give or take, for a specialty cancer drug. But what has started to happen is that for everyone else, their coverage has improved. Because in the US we're in the process of closing, or I think now we finally finished, but you know, a few years lag in claims data, we've closed what used to be called the donut hole, where there was this big coverage gap where patients had to pay a large amount out of pocket for drugs. So there might therefore be a narrowing of the difference, let's say between our low income subsidy participants, the lowest income patients, and then everyone else. But not so much because the low income subsidy status improved or changed, but just because the baseline level of coverage for everyone else may have improved, narrowing that gap. So I'd say that would be very possible.  And if your question is more geared towards not so much policy changes, but treatment landscape changes, I would say the big thing that I would maybe guess, and again, this is very much speculation, but you introduce the speculation in TBD on follow up. I think the big change in the landscape has been the broadening indication and uptake of immunotherapy drugs, our PD-1, PD-L1 inhibitors, for a variety of cancer types. And I think the way that that would manifest in our data, were we to repeat it in a more contemporary data set, would be, I think that the access for, let's say, that any systemic therapy among older patients might change. And that is because rather than just having your cytotoxics in hand, the clinical oncologists now know that for many cases there's if not first line therapy, then second line therapy for patients who don't qualify, you can go straight to it, to someone who's not a chemo candidate, you've got a much more tolerable treatment in your back pocket. And so I think that for patients who are more old or more comorbid, we might start to see that a greater proportion of them receive some systemic therapy, it just might not be the cytotoxic agent that is still most highly recommended. It might be, say a single agent, PD-L1 inhibitor, because their oncologist wants to be able to give them something. So I wouldn't be surprised if that gap starts to narrow as well if you're measuring no systemic therapy versus any systemic therapy. Dr. Davide Soldato: And going back to the policy part of the study that you did, do you think that the results of the study that you published in the JCO can better inform policy makers on how to make these treatments more available and be sure that the largest possible proportion of patients gets a systemic treatment and gets the optimal systemic treatment? Dr. Aaron Mitchell: Yes, I do think that this study has some direct and indirect policy implications. I think that our finding is one to highlight the low income subsidy program and maybe help it not to fly under the radar so much anymore. I think all the work that has been done on how much it has helped patients who need oral cancer medications is great, and it shows how beneficial this program can be. We're now shining the light kind of everywhere else and saying, “Okay. That's great. Here's how well it can work when it covers an oral drug, but we've got this group of low income patients who are still at need and they're still very clearly not able to access everything else. When it's not axitinib that they need, it's a pembrolizumab, they're still very much behind the curve and they need some help.” So I think that's one thing just to call attention to this as an ongoing problem. Low income patients, it's not a solved problem yet. It's something that needs further attention.  And then for direct policy implications that are on the table, I think we're about to see the Medicare program be able to start negotiating not just Part D drugs, but also in future years, Part B covered drugs and try to lower the price for everyone, both for insurance, both for Medicare itself. And then to the extent that that boils over to the patient's out of pocket responsibility, it'll start to reduce the patient out of pocket costs as well. So I think we can look forward to hopefully an aggressive negotiation program by Medicare to start to directly lower the prices of Part B cancer drugs that these patients are unable to afford. Dr. Davide Soldato: Thank you very much. You did the research you published in the JCO, but you really seem very passionate about the topic of care delivery and quality of care and policy. So I just wanted to ask on a personal note, how did you come to this area of research which is frequently not one that is very cared for by oncologists? It's more frequently something that biostatisticians or public health scientists put their attention to. I just had this curiosity and I wanted to ask you if you could explain a little bit how you came to this area of research. Dr. Aaron Mitchell: Thank you for asking. That's a great question. I'll tell my favorite story about my journey there. I entered medical school planning to be a clinical investigator or maybe even a basic science researcher, and I had some background in that. I went to medical school at NYU where the teaching hospital is Bellevue, which is a large, well known public hospital within New York City. And my eyes started to open regarding the inequities in the system. You always hear about it, you read about the problems in the US healthcare system, but then when you see it on a day to day basis and you can walk four blocks from a private, very well resourced hospital to see a patient with a similar condition four blocks down the road at a under resourced public hospital getting very different treatments and receiving very different outcomes, the injustice in the system really hits you on a visceral level. And it was really, I would say, as soon as I started my clinical rotations in medical school that I realized maybe that's where I can make the most impact with my career and just really fell into it. By the time I was done with medical school, I then knew that I wanted to do something that was in the health policy space. And then by the time I was done with residency, I was like, “Oh, someone had mentioned the words health services research” and the light went on. It's like, “Oh, that's me. That's what I want to do.” Dr. Davide Soldato: Thank you very much. That was a nice story. And I really think that we should all work towards trying to make sure that the inequities inside of the system are eliminated as much as possible.  So I think that this concludes our interview for today. So thank you again, Dr. Mitchell, for joining us. Dr. Aaron Mitchell: You're very welcome and thank you so much for your interest. Dr. Davide Soldato: We appreciate you sharing more on your JCO article titled, “Quality of Treatment Selection for Medicare Beneficiaries with Cancer.”  If you enjoy our show, please leave us a rating and review and be sure to come back for another episode. You can find all ASCO shows at asco.org/podcasts.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinion, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.

Healthcare is often a tangled web of bureaucracy and inefficiencies. In this week's episode, both of our storytellers share their experiences navigating its many flaws. Part 1: Zoe Wisnoski's takes matters into her own hands when her son has months of ongoing fevers. Part 2: During the pandemic, epidemiologist Bryon Backenson becomes disheartened when the public stops cooperating with public health authorities. Zoe Wisnoski is a seeker of stories, adventure, travel, and moments that stick with you. She stumbled into the world of storytelling through a training put on by Story Collider. Her passion for activism buoyed by a penchant for oversharing has finally found a home. Formerly a feminist policy analyst with a Masters in Public Policy from the Humphrey School of Public Affairs, now a full time - still feminist - mother, Zoe spends her time attempting to create joy amidst utter chaos. When her son was diagnosed with the super rare, to date minimally understood, genetic disease Tatton Brown Rahman Syndrome (TBRS), Zoe reoriented her educational and professional background to meeting his needs and volunteering with the TBRS Community, the nonprofit aimed at supporting families and advancing research for TBRS. In 2024 she joined the board of directors and continues to search for answers. Bryon Backenson is an epidemiologist. He is currently the director of the Bureau of Communicable Disease Control at the New York State Department of Health. He and his team investigate, respond to, and research infectious disease outbreaks. He is also a professor in the University at Albany College of Integrated Health Sciences, where he teaches in the Department of Epidemiology and Biostatistics. When not thinking about disease, he spends his time hiking, fishing, and reading. While he talks about epidemiology and infectious diseases all the time in classes, meetings, and webinars, this is the first time he's tried to tell his own story in this kind of format. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode Dr. Ted O'Connell breaks down Biostatistics questions 7, 8, and 9 from our online question bank. Our Websites MedPrepToGo Website BookRevision.com Dr. O'Connell's Website Dr. Dasgupta's Website Other Podcasts USMLE Step 1 Ad-Free Bundle Crush Step 1 Step 2 Secrets Beyond the Pearls The Dr. Raj Podcast Beyond the Pearls Premium USMLE Step 3 Review Dr. Ted O'Connell Dr. O'Connell is the Founding Program Director of the Family Medicine Residency Training Program at Kaiser Permanente Napa-Solano and Chief of the Department of Family and Community Medicine at Kaiser Permanente Vallejo. He is an Associate Clinical Professor in the Department of Family and Community Medicine at the UC San Francisco School of Medicine and an Associate Clinical Professor in the Department of Family Medicine at the UC Davis School of Medicine. Dr. O'Connell has previously been on the teaching staff at the UCLA and Drexel University Schools of Medicine. Dr. Raj Dasgupta Dr. Dasgupta is an ABIM Quadruple board-certified physician specializing in internal medicine, pulmonology, critical care, and sleep medicine. He practices at the University of Southern California, where he is an associate professor of clinical medicine, assistant program director of the Internal Medicine Residency Program, and the associate program director of the Sleep Medicine Fellowship. Dr. Dasgupta is an active clinical researcher and has been teaching around the world for more than 18 years. Legal/Credits All information is for entertainment and educational purposes only and is not intended as medical advice. Produced by: Christopher Breitigan Intro/Outro music: "Digital Journey" by Tim Beek (timbeek.com) Learn more about your ad choices. Visit megaphone.fm/adchoices

Public Health Careers podcast episode with Eric J. Daza, DrPH, MPS

Send us a textIn Decoding Medical Research part 2 Doctors Koren and Labos venture further into the world of medical research with an eye-opening discussion salt, heart health and inflammation. Listen now to discover the hidden truths about sodium intake and its complex relationship with your health. With most of us consuming far more sodium than recommended, the episode promises to unravel the delicate balance needed in our diets. You'll learn why some groups, like athletes or those with specific medical needs, might need more sodium and how government initiatives aim to swap sodium with potassium in processed foods to benefit heart health. This isn't just another discussion on salt—it's a comprehensive exploration of how tailored medical advice can make all the difference.You'll also get an intriguing comparison of the US and Canadian healthcare systems, inspired by insights from a newly released book. This episode is brimming with knowledge and practical advice, guaranteed to leave you with a clearer understanding of these pivotal health issues. Tune in and enrich your perspective by subscribing to our podcast or visiting MedEvidence.com.Dr. Christopher Labos is a cardiologist with a master's degree in Epidemiology. He is a columnist with the Montreal Gazette and Medscape, featured on the Sunday Morning House Call on CJAD radio, and has a regular TV segment with CTV Montreal and CBC Morning Live. He is an associate with the McGill Office of Science and Society and co-hosts the award-winning podcast “The Body of Evidence.”  He is the author of “Does Coffee Cause Cancer?”, a story about food epidemiology and why food headlines are usually wrong. He is a course lecturer in the Department of Epidemiology, Biostatistics and Occupational Health at McGill University and he occasionally practices as a cardiologist so he can buy groceries. To date no one has asked him for his autograph.Connect with Dr. Christopher LabosTwitter/X: @‌drlabosColumnist: Montreal GazetteCo-host: The Body of EvidenceAuthor: Does Coffee Cause Cancer?Recording Date: September 11, 2024Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on AppleWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramTwitterLinkedInWant to learn more checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Lynne Peeples is a freelance science journalist, specialising in the environment, public health and medicine. She holds a M.S. in Biostatistics from Harvard and an M.A. in Science Journalism from New York University. Her writing has appeared in Huffington Post, Nature, Scientific American and The Atlantic, amongst others. A 2020-2021 MIT Knight Science Journalism fellow and a finalist for the 2018 National Association of Science Writers long-form reporting award, on this episode of Little Atoms she talks to Neil Denny about her new book The Inner Clock: Living in Sync With Our Circadian Rhythms. Hosted on Acast. See acast.com/privacy for more information.

Send us a textUnlock the secrets of medical research with us as we welcome the insightful Dr. Christopher Labos, a cardiologist from Montreal who navigated a unique path from clinical practice to mastering epidemiology. Discover how his expertise empowers him to dissect complex studies, such as the impact of berry consumption on heart health, and how he became a trusted voice during the COVID-19 pandemic. This episode promises to enrich your understanding of evidence-based medicine and the critical role of science communication in public health.Join Dr. Michael Koren and Dr. Labos as they unravel the mysteries of statistics in medical research. From breaking down the differences between relative and absolute risk reduction to demystifying odds and risk ratios, we share practical insights and humor to help you grasp these vital concepts. Learn about the common pitfalls in data interpretation that both physicians and patients need to recognize. With references to popular culture and personal anecdotes, we aim to arm you with the knowledge to make informed medical decisions.Dr. Christopher Labos is a cardiologist with a master's degree in Epidemiology. He is a columnist with the Montreal Gazette and Medscape, featured on the Sunday Morning House Call on CJAD radio, and has a regular TV segment with CTV Montreal and CBC Morning Live. He is an associate with the McGill Office of Science and Society and co-hosts the award-winning podcast “The Body of Evidence.”  He is the author of “Does Coffee Cause Cancer?”, a story about food epidemiology and why food headlines are usually wrong. He is a course lecturer in the Department of Epidemiology, Biostatistics and Occupational Health at McGill University and he occasionally practices as a cardiologist so he can buy groceries. To date no one has asked him for his autograph.Connect with Dr. Christopher LabosTwitter/X: @‌drlabosColumnist: Montreal GazetteCo-host: The Body of EvidenceAuthor: Does Coffee Cause Cancer?Recording Date: September 11, 2024Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on AppleWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramTwitterLinkedInWant to learn more checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Dr. Farley R. Cleghorn, born in Trinidad, embarked on his medical journey at the University of the West Indies (UWI), graduating with honors and a Surgery Gold Medal in 1982. Early in his career, he delved into hematology at the Port-of-Spain General Hospital, focusing on lymphoma and leukemia, before undertaking a fellowship in retrovirology with Professor Courtenay Bartholomew during what he fondly recalls as the "golden age" of retrovirus research from 1986 to 1990. Dr. Cleghorn was trained in internal medicine and infectious diseases, culminating in a fellowship at the U.S. National Institutes of Health (NIH) at the National Cancer Institute. His academic achievements were further bolstered by a Master of Public Health (MPH) in Epidemiology and Biostatistics from the Johns Hopkins School of Public Health, where he was inducted into the Alpha Delta Omega honor society. His journey led him through significant roles at Johns Hopkins University and the University of Maryland Medical Center/Institute of Human Virology. At the latter, he served as Assistant Professor of Epidemiology & Prevention from 1996 to 2004, fostering extensive collaborations with the Medical Research Foundation of Trinidad and Tobago and the University of the West Indies, where he also served as an external examiner. Respected as health diplomat, Dr. Cleghorn was Global Head of Palladium until his retirement in June 2024, he led interdisciplinary teams across the U.S., Europe, Middle East, and Australia/Pacific, pioneering transformative health programs. His work spanned strategy execution consulting, international consulting, impact investment, and training, focusing on sustainable health systems, implementation science, and health promotion. Dr. Cleghorn has been recognized as a thought leader and systems thinker in global health systems, population health, HIV/AIDS, infectious diseases, pathogenesis, and clinical vaccine trials. His expertise earned him numerous accolades, a nominee for the SEA Crystal award in Spain, and a winner in the Gabriella Award in Chile, including the Chancellor's Award for Excellence in Global Health Research and Delivery in 2023. His philanthropic endeavors underscore his commitment to medical education and community welfare. His generous donation to the University of the West Indies Medical Alumni Association established an endowment for scholarships, reflecting his dedication to nurturing future medical professionals. Also an humanitarian he has mentored countless young health professionals and contributed significantly to global health diplomacy. His compassion and dedication to improving healthcare, especially in underserved communities like his native Trinidad, exemplify his profound commitment to humanity. In sum, Dr. Farley R. Cleghorn's career is a testament to the transformative power of medicine and public health, driven by a steadfast belief in the potential of healthcare to enrich lives globally. His legacy as a scholar, mentor, and advocate for equitable healthcare continues to inspire generations of healthcare professionals worldwide. As Chris LeGrand, Chief Executive Officer at BroadReach Group, who has known him for 20 years, serving alongside in Futures Group, now The Palladium, as chief technical officer, accomplishing many things together said……“More than his brilliance and professional impact, what I have come to love of Farley is his heart. Farley has a heart for humans and our human condition. Where others see only human tragedy and despair Farley sees community and possibility”

For this episode, we discuss the roles and sensitivity of mitochondria with Dr. Richard Frye, MD, PhD. Dr. Frye received an MD and a PhD in Physiology and Biophysics from Georgetown University. He is board certified in Pediatrics, Neurology with special competence in Child Neurology, and as a Certified Principal Investigator. In addition, he has a Masters in Biomedical Sciences and Biostatistics from Drexel University. Dr. Frye has over 300 publications in leading journals and book chapters.He currently sees patients as a Neurologists and Director of Research at Rossingnol Medical Center and at Neurodevelopmental Precision Medicine. In 2022, Dr. Frye co-founded the Autism Discovery and Treatment Foundation where they are dedicated to discover biomarkers, metabolic endophenotypes, and treatments for neurodevelopemental disorders.Dr. Frye shares many figures during the conversation so the listener can follow along.Dr, Richard Frye https://drfryemdphd.comCV https://wparticles.seek2understand.org/wp-content/uploads/2023/02/DrFryeCVJan2023.pdfRossingnol Medical Center Facebook https://www.facebook.com/RossignolMedicalCenterNeurobiology of Disease 2024 paper https://www.sciencedirect.com/science/article/pii/S0969996124001190?via%3DihubAutism and GI, and exploring how changes in Light have major implications (Apple) https://podcasts.apple.com/us/podcast/from-the-spectrum-finding-superpowers-with-autism/id1737499562?i=1000664349495 0:00 Dr. Richard Frye6:13 Intro into mitochondria & energy production, various disease & dysfunction11:16 Mitochondrial DNA, sensitivity, and the roles with epigenetics16:16 Biomarkers of mitochondrial dysfunction, delicate delivery (space and time) into the electron transport chain20:58 Cytochrome C Oxidase (complex IV); Carnitine, Fat, and Creatine26:57 Molecules connected to aging & cellular respiration, environemental signals implicating mitochondria30:26 Terrible Trio: oxidative stress, mitochondria dysfunction, immune/inflammation, DAMPS & inflammation34:29 Environmental risks for the Embryo, overreactivity of mitochondria (200%) and physiological insults and regression42:50 Tryptophan (aromatic amino acid), NAD, and Gastrointestinal biosynthesis45:52 Light as an environmental change factoring into the Autistic Phenotype, Infant Tree and Adult Tree examples; Vitamin D (skin & brain are connected through Neuroectoderm)54:54 Future Research59:58 Wrap up, Reviews/RatingsX: https://twitter.com/rps47586Hopp: https://www.hopp.bio/fromthespectrumemail: info.fromthespectrum@gmail.com

Research uncovers the secrets to thriving as individuals and communities. What are the ingredients of a life that will help us to thrive as people? How do we go about cultivating those ingredients? What does it mean to truly flourish as a person?Policy makers are interested in these questions. So are educationalists. And as individuals it's a topic that we increasingly seek answers to. People these days are very focused on wellbeing and what will aid or hinder that.Tyler VanderWeele's research in this area engages huge data sets and deep analysis. He is Professor of Epidemiology in the Departments of Epidemiology and Biostatistics at the Harvard T.H. Chan School of Public Health, and Director of the Human Flourishing Program.Professor VanderWeele's many insights into what makes for human flourishing are worth hearing. Some might come as a surprise!

About this episode: When evaluating programs, policies, and interventions, how do you know if they're working? In today's episode: The science (and art!) of biostatistics, and an exploration of the question: How can we design studies to find out if there really is a relationship between A and B? Guest: Elizabeth Stuart is the chair of the department of Biostatistics at the Johns Hopkins Bloomberg School of Public Health. Host: Dr. Josh Sharfstein is vice dean for public health practice and community engagement at the Johns Hopkins Bloomberg School of Public Health, a faculty member in health policy, a pediatrician, and former secretary of Maryland's Health Department. Show links and related content: Better Debates, Better Decisions: Causality Assessment in Population Health—The Milbank Quarterly Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on X @‌JohnsHopkinsSPH on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed

We often don't have the opportunity to hear directly from students about inclusive teaching practices. In this episode, Tracie Addy, Derek Dube, and Khadijah A. Mitchell, the authors of Enhancing Inclusive Instruction, join us to explore how student perceptions of inclusive teaching practices align with the growing consensus on what constitutes inclusive teaching.  After serving as the Associate Dean of Teaching and Learning at Lafayette College, Tracie will be transitioning to a new role this summer as the Director of the Institute for Teaching, Learning, and Inclusive Pedagogy at Rutgers University - New Brunswick. Derek Dube is an Associate Professor of Biology and the Director of the First-Year Seminar Program at the University of St. Joseph in Connecticut. Khadijah A. Mitchell is an Assistant Professor in the Cancer Prevention and Control Program at the Fox Chase Cancer Center in the Temple University Health System and Affiliated Faculty in the Department of Epidemiology and Biostatistics at the Temple University College of Public Health. A transcript of this episode and show notes may be found at http://teaforteaching.com.

In this episode, I'm joined by cognitive neuroscientist, Adam Omary. This guy is extremely smart so be prepared. We had an interesting conversation about his experience growing from an incel to Harvard graduate student, his experience learning to socialize, the Twin Study, the effects of prenatal hormones during brain development, the causes of gender dysphoria, how cortisol affects the brain, recovering from puberty blockers, and much more. Enjoy! Adam Omary is a Psychology Ph.D. student at Harvard University, where he conducts research in the Affective Neuroscience & Development Laboratory under the mentorship of Dr. Leah Somerville. He attended the University of Southern California as a QuestBridge Scholar and graduated with a B.A. in Cognitive Science and M.S. in Biostatistics. —Check Out Our Sponsors— - Order my hangover supplement, After Party on https://bit.ly/3VJ0UnD and Amazon https://a.co/d/6OGdTrT. Be sure to leave a review! - Air Oasis' iAdaptAir Purifier at https://www.airoasis.com/pages/mp code MP for 10% off —Visit Adam's Links— Website: https://adamomary.com Substack: https://naturednurture.substack.com YouTube: https://youtube.com/c/thenaturenurturepodcast —Follow Me— All Platforms: https://linktr.ee/mikhailapeterson Instagram: https://instagram.com/mikhailapeterson TikTok: https://tiktok.com/@mikhailapeterson Website: https://mikhailapeterson.com Lion Diet: https://liondiet.com Biotoxin: https://biotoxin.com Facebook: https://facebook.com/mikhailapete​rsonpodcast X: https://twitter.com/MikhailaFuller Telegram: https://t.me/mikhailapeterson​​ —Chapters— [0:00] Intro [1:15] What is the Twin Study? [9:36] Correlation between gender identity and sexual orientation [14:57] Prenatal hormones during brain development [23:22] Why Adam studied gender dysphoria [26:37] What does cortisol/high-level of stress do to the brain? [30:30] SSRIs during brain development [36:30] Adam's background and childhood [40:51] How catfishing and red pill helped social development [47:10] Measuring brain activity for accurate hormone levels [51:05] Dopamine release levels between men and women [57:18] Adam's Harvard experience [1:02:02] How has AI impacted universities? [1:03:01] Adam's faith and spirituality journey [1:11:57] Can adolescents recover from puberty blockers? [1:20:44] Gender dysphoria and social influence

Alyssa Bilinski, Peterson Family Assistant Professor of Health Policy, and Assistant Professor of Biostatistics, at Brown University School of Public Health. Her research focuses on developing novel methods for policy evaluation and applying these to identify interventions that most efficiently improve population health and well-being. Episode notes: PNAS paper: https://www.pnas.org/doi/full/10.1073/pnas.2302528120 Shuo Feng's pre-print: https://www.medrxiv.org/content/10.1101/2024.04.08.24305335v1 Our uncertainty paper: https://pubmed.ncbi.nlm.nih.gov/33475686/ Follow along on Twitter: Alyssa: @ambilinski The American Journal of Epidemiology: @AmJEpi Ellie: @EpiEllie Lucy: @LucyStats

Edward Kennedy Associate Professor, Department of Statistics & Data Science, Carnegie Mellon. Episode notes: ehkennedy.com Evaluating a Targeted Minimum Loss-Based Estimator for Capture-Recapture Analysis: An Application to HIV Surveillance in San Francisco, California: https://academic.oup.com/aje/article/193/4/673/7425624 Doubly Robust Capture-Recapture Methods for Estimating Population Size: https://www.tandfonline.com/doi/full/10.1080/01621459.2023.2187814 Follow along on Twitter: The American Journal of Epidemiology: @AmJEpi Ellie: @EpiEllie Lucy: @LucyStats

Yascha Mounk and Vinay Prasad assess the strengths and weaknesses of America's public health response. Vinay Prasad MD, MPH is a hematologist-oncologist and Professor in the Department of Epidemiology and Biostatistics at the University of California San Francisco.   In this week's episode, Yascha Mounk and Vinay Prasad discuss the impact and efficacy of mask mandates and lockdowns; how the stifling of dissenting views among doctors and scientists harmed decision-making; and how we can improve our readiness for the next pandemic. This transcript has been condensed and lightly edited for clarity. Please do listen and spread the word about The Good Fight. If you have not yet signed up for our podcast, please do so now by following this link on your phone. Email: podcast@persuasion.community  Website: http://www.persuasion.community Podcast production by Jack Shields, and Brendan Ruberry Connect with us! Spotify | Apple | Google Twitter: @Yascha_Mounk & @joinpersuasion Youtube: Yascha Mounk LinkedIn: Persuasion Community Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices